The not-so innocent bystander: The microenvironment as a therapeutic target in cancer

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 1, 2003, Pages 71-88

  Erickson, Anna C ^a   Barcellos Hoff, Mary Helen ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Basement membrane; Breast cancer; Extracellular matrix (ECM); Microenvironment; Stroma; TGF

Indexed keywords

ALPHA INTERFERON; ANASTELLIN; BATIMASTAT; DECORIN; FIBRONECTIN; GELATINASE B; GLYCAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GROWTH FACTOR; INTEGRIN; LAMININ; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; PROTEOGLYCAN; RECEPTOR; SYNDECAN 1; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

BREAST CANCER; BURSITIS; CARCINOGENESIS; CHEMICAL COMPOSITION; DEGRADATION; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY CELL; MICROENVIRONMENT; MUSCULOSKELETAL DISEASE; NONHUMAN; PROTEIN STRUCTURE; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; STROMA; TENDINITIS; TUMOR VASCULARIZATION;

BREAST NEOPLASMS; CELL COMMUNICATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYTOKINES; DRUG DESIGN; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; GROWTH SUBSTANCES; HUMANS; LAMININ; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PROTEOGLYCANS; STROMAL CELLS; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0037312899     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.1.71     Document Type: Review

References (184)

1. HULKA BS, STARK AT: Breast cancer: cause and prevention. Lancet (1995) 346:883-887.
2. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
3. EVAN G, LITTLEWOOD T: A matter of life and cell death. Science (1998) 281:1317-1322.
4. PIERCE GB, SHIKES R, FINK LM: Cancer: A Problem of Developmental Biology. Englewood Cliffs, Inc., NJ, Prentice-Hall, (1978).
5. DVORAK HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. (1986) 315:1650-1659.
6. WONG YC, WANG YZ: Growth factors and epithelial-stromal interactions in prostate cancer development. Int. Rev. Cytol. (2000) 199:65-116.
7. SILBERSTEIN GB: Role of the stroma in mammary development. Breast Cancer Res. (2001) 3:218-223.
8. ERICKSON AC, COUCHMAN JR: Still more complexity in mammalian basement membranes. J. Histochem. Cytochem. (2000) 48:1291-1306.
9. KUHN K: The classical collagens: Types I, II, III. In: Structure and Function of Collagen Types. Mayne R, Burgeson R (Eds), Academic Press, Florida (1987):1-42.
10. HYNES RO: Fibronectins. Springer-Verlag, New York (1990).
11. FLAUMENHAFT R, RIFKIN DB: The extracellular regulation of growth factor action. Mol. Biol. Cell(1992) 3:1057-1065.
12. BISSELL MJ: The differentiated state of normal and malignant cells or how to define a 'normal' cell in culture. Int. Rev. Cytol. (1981) 70:27-100.
13. WISEMAN BS, WERB Z: Stromal effects on mammary gland development and breast cancer. Science (2002) 296:1046-1049.
14. BARCELLOS-HOFF MH, AGGELER J, RAM TG, BISSELL MJ: Functional differentiation and alveolar morphogenesis of primary mammary epithelial cells cultures on reconstituted basement membrane. Development (1989) 105:223-235.
15. WICHA MS, LIOTTA LA, VONDERHAAR BK, KIDWELL WR: Effects of inhibition of basement membrane collagen deposition on rat mammary gland development. Dev. Biol. (1980) 80:253-266.
16. SILBERSTEIN GB, DANIEL CW: Glycosaminoglycans in the basal lamina and extracellular matrix of the developing mouse mammary duct. Dev. Biol. (1982) 90:215-222.
17. DECOSSE JJ, GOSSENS CL, KUZMA JF, UNSWORTH D: Breast cancer: induction of differentiation by embryonic tissue. Science (1973) 181:1057-1058.
18. COOPER M, PINKUS H: Intrauterine transplantation of rat basal cell carcinoma as a model for reconversion of malignant to benign growth. Cancer Res. (1977) 37:2544-2552.
19. KAMIYA K, YASUKAWA-BARNES J, MITCHEN JM, GOULD MN, CLIFTON KH: Evidence that carcinogenesis involves an imbalance between epigenetic high-frequency initiation and suppression of promotion. Proc. Natl. Acad. Sci. USA (1995) 92:1332-1336.
20. MORGAN JE, GROSS JG, PAGEL CN et al.: Myogenic cell proliferation and generation of a reversible tumorigenic phenotype are triggered by preirradiation of the recipient site. J. Cell Biol. (2002) 157:693-702.
21. FUJII H, CUNHA GR, NORMAN JT: The induction of adenocarinomatous differentiation in neoplastic bladder epithelium by an embryonic prostatic inducer. J. Urology (1982) 128:858-861.
22. ROSSI L, REVERBERI D, PODESTA G, LASTRAIOLI S, CORVO R: Co-culture with human fibroblasts increases the radiosensitivity of MCF-7 mammary carcinoma cells in collagen gels. Int. J. Cancer (2000) 85:667-673.
23. JAVAHERIAN A, VACCARIELLO M, FUSENIG N, GARLICK J: Normal keratinocytes suppress early stages of neoplastic progression in stratified epithelium. Cancer Res. (1998) 58:2200-2208.
24. RUBIN H: Cancer as a dynamic developmental disorder. Cancer Res. (1985) 45:2935-2942.
25. RUBIN H: Selected cell and selective microenvironment in neoplastic development. Cancer Res. (2001) 61:799-807.
26. BAUER G: Elimination of transformed cells by normal cells: a novel concept for the control of carcinogenesis. Histol. Histopathol. (1996) 11:237-255.
27. MUELLER MM, PETER W, MAPPES M et al.: Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am. J. Pathol. (2001) 159:1567-1579.
28. ELLIOTT BE, MAXWELL L, ARNOLD M, WEI WZ, MILLER FR: Expression of epithelial-like markers and class I major histocompatibility antigens by a murine carcinoma growing in the mammary gland and in metastases: orthoropic site effects. Cancer Res. (1988) 48:7237-7245.
29. SAKAKURA T, SAKAGAMI Y, NISHIZUKA Y: Accelerated mammary cancer development by fetal salivary mesenchyme isografted to adult mouse mammary epithelium. J. Natl. Cancer Inst. (1981) 66:953-959.
30. DEOME KB, MIYAMOTO MJ, OSBORN RC, GUZMAN RC, LUM K: Detection of inapparent nodule transformed cells in the mammary gland tissues of virgin female BALB/cfC3H mice. Cancer Res. (1978) 38:2103-2111.
31. ETHIER SP, ULLRICH RL: Factors influencing expression of mammary ductal dysplasia in cell dissociation-derived murine mammary outgrowths. Cancer Res. (1984) 44:4523-4527.
32. LIOTTA LA, RAO CN, BARSKY SH: Tumor invasion and the extracellular matrix. Lab. Invest. (1983) 49:636-649.
33. SAKAKURA T, SAKAGAMI Y, NISHIZUKA Y: Acceleration of mammary cancer development by grafting of fetal mammary mesenchymes in C3H mice. Gann. (1979) 70:459-466.
34. VAN DEN HOOF A: Stromal involvement in malignant growth. Adv. Cancer Res. (1988) 50:159-196.
35. LIN EY, NGUYEN AV, RUSSELL RG, POLLARD JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. (2001) 193:727-740.
36. COUSSENS LM, WERB Z: Inflammatory cells and cancer: think differend! J. Exp. Med. (2001) 193:F23-F26.
37. JACOBS TW, SCHNITT SJ, TAN X, BROWN LF: Radial scars of the breast and breast carcinomas have similar alterations in expression of factors involved in vascular stroma formation. Hum. Pathol. (2002) 33:29-38.
38. OLUMI AF, DAZIN P, TLSTY TD: A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death. Cancer Res. (1998) 58:4525-4530.
39. OLUMI AF, GROSSFELD GD, HAYWARD SW et al.: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. (1999) 59:5002-5011.
40. VALENTI MT, AZZARELLO G, BALDUCCI E et al.: Conditioned medium from MCF-7 cell line induces myofibroblast differentiation, decreased cell proliferation, and increased apoptosis in cultured normal fibroblasts but not in fibroblasts from malignant breast tissue. Histochem. J. (2001) 33:499-509.
41. SINGER CF, KRONSTEINER N, MARTON E et al.: MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res. Treat. (2002) 72:69-77.
42. SCHOR SL, SCHOR AM, DURNING P, RUSHTON G: Skin fibroblasts obtained from cancer patients display foetal-like migratory behaviour on collagen gels. J. Cell Sci. (1985) 73:235-244.
43. SCHOR S, SCHOR A: Phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res. (2001) 3:373-379.
44. HAGGIE JA, SCHOR SL, HOWELL A, BIRCH JM, SELLWOOD RAS: Fibroblasts from relatives of hereditary breast cancer patients display fetal-like behavior in vitro. Lancet (1987) 1:1455-1457.
45. SCHOR AM, RUSHTON G, FERGUSON JE et al.: Phenotypic heterogeneity in breast fibroblasts: functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. Int. J. Cancer (1994) 59:25-32.
46. KOPELOVICH L, PFEFFER LM, BIAS N: Growth characteristics of human skin fibroblasts in vitro: a simple experimental approach for the identification of hereditary adenomatosis of the colon and rectum. Cancer (1979) 43:218-223.
47. RASHEED S, GARDNER MB: Growth properties and susceptibility to viral transformation of skin fibroblasts from individuals at high genetic risk for colorectal cancer. J. Natl. Cancer Inst. (1981) 66:43-49.
48. MOINFAR F, MAN YG, ARNOULD L et al.: Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. (2000) 60:2562-2566.
49. GRADY WM, MARKOWITZ SD: Genetic and epigenetic alterations in colon cancer. Ann. Rev. Genom. Hum. Genet. (2002) 3:101-128.
50. GORDON MY, DOWDING CR, RILEY GP, GOLDMAN JM, GREAVES MF: Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature (1987) 328:342-344.
51. BHATIA R, MCCARTHY JB, VERFAILLIE CM: Interferon-alpha restores normal beta 1 integrin-mediated inhibition of haematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukaemia. Blood (1996) 87:3883-3891.
52. BRATIA R, MUNTHE HA, FORMAN SJ: Abnormal growth factor modulation of beta 1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors. Br. J. Haematol. (2001) 115:845-853.
53. GREENBERGER J, EPPERLY M, ZEEVI A et al.: Stromal cell involvement in leukaemogenesis and carcinogenesis. In Vivo (1996) 10:1-17.
54. HODGES GM, HICKS RM, SPACEY GD: Epithelial-stromal interactions in normal and chemical carcinogen-treated adult bladder. Cancer Res. (1977) 37:3720-3730.
55. CHA RS, THILLY WG, ZARBL H: N-nitroso-N-methylurea-induced rat mammary tumors arise from cells with preexisting oncogenic Hras1 gene mutations. Proc. Natl. Acad. Sci. USA (1994) 91:3749-3753.
56. ZHANG W, REMENYIK E, ZELTERMAN D, BRASH DE, WIKONKAL NM: Escaping the stem cell compartment: sustained UVB exposure allows p53-murant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations. Proc. Natl. Acad. Sci. USA (2001) 98:13948-13953.
57. BARCELLOS-HOFF MH, RAVANI SA: Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. (2000) 60:1254-1260.
58. BOWDEN GT, JAFFE D, ANDREWS K: Biological and molecular aspects of radiation carcinogenesis in mouse skin. Rad. Res. (1990) 121:235-241.
59. MARTIN M, REMY J, DABURON F: In vitro growth potential of fibroblasts isolated from pigs with radiation-induced fibrosis. Int. J. Rad. Biol. (1986) 49:821-828.
60. PANIZZONI RG, HANSON WR, SCHWARTZ DE, MALKINSON FD: Ionizing radiation induces early, sustained increases in collagen biosynthesis: a 48-week study of mouse skin and skin fibroblast cultures. Rad. Res. (1988) 116:145-156.
61. BARCELLOS-HOFF MH: The potential influence of radiation-induced microenvironments in neoplastic progression. J. Mammary Gland Biol. Neoplasia (1998) 3:165-175.
62. LEE E-H, BARCELLOS-HOFF MH, CHEN L-H, PARRY G, BISSELL MJ: Transferrin is a major mouse milk protein and is synthesized by mammary epithelial cells. In Vitro Cell. Dev. Biol. (1987) 23:221-226.
63. PETERSEN OW, RONNOV-JESSEN L, HOWLETT AR, BISSELL MJ: Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. USA (1992) 89:9064-9068.
64. WEAVER VM, PETERSEN OW, WANG F et al.: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. (1997) 137:231-245.
65. SIEGAL GP, BARSKY SH, TERRANOVA VP, LIOTTA LA: Stages of neoplastic transformation of human breast tissue as monitored by dissolution of basement membrane components. An immunoperoxidase study. Invasion Metastasis (1981) 1:54-70.
66. LEWKO W, LIOTTA LA, WICHA MS, VONDERHAAR BK, KIDWELL WR: Sensitivity of N-nitrosomethylurea-induced rat mammary tumors to cis-hydroxyproline, an inhibitor of collagen production. Cancer Res. (1981) 41:2855-2862.
67. SYMPSON CJ, BISSELL MJ, WERB Z: Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Sem. Cancer Biol. (1995) 6:159-163.
68. ROMBERGER DJ: Fibronectin. Int. J. Biochem. Cell Biol. (1997) 29:939-943.
69. TUMOVA S, WOODS A, COUCHMAN JR: Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int. J. Biochem. Cell Biol. (2000) 32:269-288.
70. URTREGER A, PORRO F, PURICELLI L et al.: Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. Int. J. Cancer (1998) 78:233-241.
71. WERBAJH SE, URTREGER AJ, PURICELLI LI et al.: Downregulation of fibronectin transcription in highly metastatic adenocarcinoma cells. FEBS Lett. (1998) 440:277-281.
72. HAYMAN E, ENGVALL E, RUOSLAHTI E: Butyrate restores fibronectin at cell surface of transformed cells. Exp. Cell Res. (1980) 127:478-481.
73. PASQUALINI R, BOURDOULOUS S, KOIVUNEN E, WOODS V, RUOSLAHTI E: A polymeric form of fibronectin has antimetastic effects against multiple tumor types. Nat. Med. (1996) 2:1197-1203.
74. YI M, RUOSLAHTI E: A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc. Natl. Acad. Sci. USA (2001) 98:620-624.
75. SCHEDIN P, STRANGE R, MITRENGA T, WOLFE P, KAECK M: Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J. Cell Sci. (2000) 113:795-806.
76. MARIANI G, LASKU A, PAU A et al.: A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99M-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer (1997) 80:2482-2489.
77. MARIANI G, LASKU A, BALZA E et al.: Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer (1997) 80:2378-2384.
78. KOUKOULIS GK, HOWEEDY AA, KORHÔNEN M, VIRTANEN I, GOULD VE: Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J. Submicrosc. Cytol. Pathol. (1993) 25:285-295.
79. MIDULLA M, VERMA R, PIGNATELLI M et al.: Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res. (2000) 60:164-169.
80. + fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupuytren). Histochem. Cell Biol. (1998) 109:249-255.
81. MANABE R-I, OH-E N, MAEDA T, FUKADA T, SEKIGUCHI K: Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J. Cell Biol. (1997) 139:295-307.
82. CARNEMOLLA B, LEPRINI A, ALLEMANNI G, SAGINATI M, ZARDI L: The inclusion of the Type III repeat ED-B in the fibronection molecule generates conformational modifications that unmask a cryptic sequence. J. Biol. Chem. (1992) 267:24689-24692.
83. NISTA A, LEONETTI C, BERNARDINI G, MATTIONI M, SANTONI A: Functional role of alpha4beta1 ad alpha5beta1 integrin fibronectin receptors expressed on adriamycin-resistant MCF-7 human mammary carcinoma cells. Int. J. Cancer (1997) 72:133-141.
84. EKBLOM M, FALK M, SALMIVIRTA K, DURBEEJ M, EKBLOM P: Laminin isoforms and epithelial development. Ann. NY Acad. Sci. (1998) 857:194-211.
85. COLOGNATO H, YURCHENCO PD: Form and function: the laminin family of heterotrimers. Dev. Dyn. (2000) 218:213-234.
86. MINER JH, LEWIS RM, SANES JR: Molecular cloning of a novel laminin chain, α5, and widespread expression in adult mouse tissues. J. Biol. Chem. (1995) 270:28523-28526.
87. MINER JH, PATTON BL, LENTZ SI et al.: The laminin α chains: expression, developmental transitions, and chromosomal location of α1-5, identification of heterotrimeric laminins 8-11, and cloning a novel α3 isoform. J. Cell Biol. (1997) 137:685-701.
88. MAATTA M, VIRTANEN I, BURGESON R, AUTIO-HARMAINEN H: Comparative analysis of the distribution of laminin chains in the basement membranes in some malignant epithelial tumors: the α1 chain of laminin shows a selected expression pattern in human carcinomas. J. Hisotchem. Cytochem. (2001) 49:711-725.
89. MARTIN KJ, KWAN CP, NAGASAKI K et al.: Downregularion of laminin-5 in breast carcinoma cells. Mol. Med. (1998) 4:602-613.
90. HENNING K, BERNDT A, KATENKAMP D, KOSMEHL H: Loss of laminin-5 in the epithelium-stroma interface: an immunohistochemical marker of malignancy in epithelial lesion of the breast. Histopathology (1999) 34:305-309.
91. GUDJONSSON T, RONNOV-JESSEN L, BILLADSEN R et al.: Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J. Cell Sci. (2001) 115:39-50.
92. SIDHOM G, IMAM M: Evaluation of serum laminin as a tumor marker in breast cancer. Int. J. Clin. Lab. Res. (1999) 29:26-29.
93. KANEMOTO T, REICH R, ROYCE L et al.: Identification of an amino-acid sequence from the laminin α chain which stimulates metastases formation and collagenase-IV production. Proc. Natl. Acad. Sci. USA (1990) 87:2279-2283.
94. YAMAMURA K, KIBBEY MC, JUN SH, KLEINMAN HK: Effect of matrigel and laminin peptide YIGSR on tumor growth and metastasis. Cancer Biol. (1993) 4:259-265.
95. ARDINI E, SPORCHIA B, POLLEGIONI L et al.: Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragments. Cancer Res. (2002) 62:1321-1325.
96. MAGNIFICO A, TAGLIABUE E, BUTO S et al.: Peptide G, containing die binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells. J. Biol. Chem. (1996) 271:31179-31184.
97. KIM WH, SCHNAPER HW, NOMIZU M, YAMDA Y, KLEINMAN HK: Apoptosis of human fibrosarcoma cells is induced by a multimeric synthetic Tyr-Ile-Gly-Ser-Arg (YIGSR)-containing polypeptide from laminin. Cancer Res. (1994) 54:5005-5010.
98. DELEHEDDE M, LYON M, SERGEANT N, RAHMOUNE H, FERNIG DG: Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. J. Mammary Gland Biol. Neoplasia (2001) 6:253-273.
99. IOZZO RV: The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J. Biol. Chem. (1999) 274:18843-18846.
100. HITZEMAN J, WOOST PG, HOSICK HL: Correlation of hyaluronic acid accumulation and the growth of preneoplastic mammary cell in collagen: a longitudinal study. In Vitro Cell Dev. Biol. (1992) 28:284-292.
101. CHANDRASEKARAN E, DAVIDSON E: Glycosaminoglycans of normal and malignant cultured human mammary cells. Cancer Res. (1979) 39:870-880.
102. PEJLER G, DAVID G: Basement-membrane heparan sulphate with high affinity for antithrombin synthesized by normal and transformed mouse mammary epithelial cells. Biochem. J. (1987) 248:69-77.
103. STANLEY MJ, STANLEY MW, SANDERSON RD, ZERA R: Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am. J. Clin. Pathol. (1999) 112:377-383.
104. MALI M, ANDTFOLK H, MIETTINEN HM, JALKANEN M: Suppression of tumor cell growth by syndecan-1 ectodomain. J. Biol. Chem. (1994) 269:27795-27798.
105. ALEXANDER C, REICHSMAN F, HINKES M et al.: Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat. Genet. (2000) 25:329-332.
106. MATSUDA K, MARUYAMA H, GUO F et al.: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. (2001) 61:5562-5569.
107. LOPEZ-CASILLAS F, WRANA JL, MASSAGUE J: Betaglycan presents ligand to the TGFbeta signaling receptor. Cell (1993) 73:1435-1444.
108. CHAKRAVARTHY D, GREEN A, GREEN V, KERIN M, SPEIRS V: Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. Int. J. Oncol. (1999) 15:187-194.
109. BANDYOPADHYAY A, ZHU Y, MALIK S et al.: Extracellular domain of TGFbeta Type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene (2002) 21:3541-3551.
110. LEYGUE E, SNELL L, DOTZLAW H et al.: Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. (2000) 192:313-320.
111. SANTRA M, EICHSTETTER I, IOZZO RV: An anti-oncogenic role for decorin. Down-regulation of erbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J. Biol. Chem. (2000) 275:35153-35161.
112. JONES FS, JONES PL: The tenascin family of ECM glycoproteins: structure, function and regulation during embryonic development and tissue remodelling. Dev. Dyn. (2000) 218:235-259.
113. WILSON KE, BARTLETT JMS, MILLER EP et al.: Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. Br. J. Cancer (1999) 80:685-692.
114. SWINDLE CS, TRAN KT, JOHNSON TD et al.: Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J. Cell Biol. (2001) 154:459-468.
115. SCHENK S, CHIQUET-EHRISMANN R, BATTEGAY EJ: The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. Mol. Biol. Cell (1999) 10:2933-2943.
116. FORSBERG E, HIRSCH E, FROHLICH L et al.: Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc. Natl. Acad. Sci. USA (1996) 93:6594-6599.
117. SAKAKURA T, ISHIHARA A, YATANI R: Tenascin in mammary gland development: from embryogenesis to carcinogenesis. Cancer Treat. Res. (1991) 53:383-400.
118. RINEHART CA, IRIGARAY MF, LYN-COOK BD, KAUFMAN DG: An in vitro model system for the organogenesis of human edometrial secretory glands. J. Cell Biol. (1987) 105:42a.
119. MACKIE EJ, CHIQUET-EHRISMANN R, PEARSON CA et al.: Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc. Nat. Acad. Sci. USA (1987) 84:4621-4625.
120. ADAMS M, JONES JL, WALKER RA, PRINGLE JH, BELL SC: Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res. (2002) 62:3289-3297.
121. KAWAKATSU H, SHIURBA R, OBARA M et al.: Human carcinoma cells synthesize and secrete tenascin in vitro. Jpn. J. Cancer Res. (1992) 83:1073-1080.
122. ISHIHARA A, YOSHIDA T, TAMAKI H, SAKAKURA T: Tenascin expression in cancer cells and stroma of human breast and its prognostic significance. Clin. Cancer Res. (1995) 1:1035-1041.
123. SIRI A, KNAUPER V, VEIRANA N et al.: Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J. Biol. Chem. (1995) 270:8650-8654.
124. BORSI L, BALZA E, ALLEMANNI G, ZARDI L: Differential expression of the fibronectin isoform containing the ED-B oncofetal domain in normal human fibroblast cell fines originating from different tissues. Exp. Cell Res. (1992) 199:98-105.
125. HINDERMANN W, BERNDT A, BORSI L et al.: Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J. Pathol. (1999) 189:475-480.
126. DUECK M, RIEDL S, HINZ W et al.: Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int. J. Cancer (1999) 82:477-483.
127. GUY CT, CARDIFF RD, MULLER WJ: Induction of mammary tumors by expression of polymavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell Biol. (1992) 12:954-961.
128. TALTS JR, WIRL G, DICTOR M, MULLER WJ, FASSLER R: Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J. Cell Sci. (1999) 112:1855-1864.
129. STERNLICHT MD, BERGERS G: Matrix metalloproteinases as emerging targets in anticancer therapy; status and prospects. Emerging Therap. Targets (2000) 4:609-633.
130. GIANNELLI G, POZZI A, STETLER-STEVENSON WG, GARDNER HA, QUARANTA V: Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids. Am. J. Pathol. (1999) 154:1193-1201.
131. KOIVUNEN E, ARAP W, VALTANEN H et al.: Tumor targeting with a selective gelatinase inhibitor. Nat. Biotech. (1999) 17:768-774.
132. HEATH EI, GROCHOW LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs (2000) 59:1043-1055.
133. WERB Z, TREMBLE P, DAMSKY CH: Regulation of extracellular matrix degradation by cell-extracellular matrix interactions. Cell Differ. Dev. (1990) 32:299-306.
134. STERNLICHT MD, WERB Z: ECM proteinases. In: Guidebook to the extracellular matrix and adhesion proteins. Kreis T, Vale R (Eds), Oxford University Press, New York (1999):503-562.
135. BENAUD C, DICKSON RB, THOMPSON EW: Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res. Treat. (1998) 50:97-116.
136. LOCHTER A, GALOSY S, MUSCHLER J et al.: Matrix metalloproteinase stomelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and premalignant phentoype in mammary epithelial cells. J. Cell Biol. (1997) 139:1861-1872.
137. STERNLICHT MD, LOCHTER A, SYMPSON CJ et al.: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell (1999) 98:137-146.
138. THOMASSET N, LOCHTER A, SYMPSON CJ et al.: Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. J. Am. Sci. (1998) 153:457-467.
139. HAY ED: An overview of epitheliomesenchymal transformation. Acta. Anat. (Basel) (1995) 1:8-20.
140. PERL AK, WILGENBUS P, DAHL U, SEMB H, CHRISTOFORI G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 392:190-193.
141. LUKASHEV ME, WERB Z: ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. (1998) 8:437-441.
142. EGEBLAD M, WERB Z: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. (2002) 2:161-174.
143. JIANG YEA: Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res. (2001) 61:2365-2370.
144. CHIRIVI RG, GAROFALO A, CRIMMIN MJ et al.: Inhibition of the metastatic spread and growth of b16-b16 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer (1994) 58:460-464.
145. WANG X, FU X, BROWN KD, CRIMMIN MJ, HOFFMAN RM: Matrix metalloproteinase inhibitor bb-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. (1994) 54:4726-4728.
146. LOW JA, JOHNSON EA, BONE A, DICKSON RB: The matrix metalloproteinase inhibitor, batimasat (BB-94) retards human breast cancer solid growth but not ascites formation in nude mice. Clin. Cancer Res. (1996) 2:1207-1214.
147. THOMPSON EW, SLEDGE GW Jr: Towards the therapeutic targeting of matrix metalloproteinases in breast cancer. In: Breast Cancer Molecular Genetics, Pathogenesis and Therapeutics. Bowcock AM (Ed), Humana Press, New Jersey (1999):437-452.
148. ROBERTS AB, ANZANO MA, LAMB LC, SMITH JM, SPORN MB: New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissue. Proc. Natl. Acad. Sci. USA (1981) 78:5339-5343.
149. NATHAN C, SPORN M: Cytokines in context. J. Cell Biol. (1991) 113:981-986.
150. FLAUMENHAFT R, ABE M, MIGNATTI P, RIFKIN DB: Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity. J. Cell Biol. (1992) 118:901-909.
151. DERYNCK R, JARRETT JA, CHEN EY et al.: Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 316:701-705.
152. WAKEFIELD LM, SMITH DM, FLANDERS KC, SPORN MB: Latent transforming growth factor-β from human platelets: a high molecular weight complex containing precursor sequences. J. Biol. Chem. (1988) 263:7646-7654.
153. FLAUMENHAFT R, RIFKIN DB: Cell density dependent effects of TGF-β demonstrated by a plasminogen activator-based assay for TGF-β. J. Cell Physiol. (1992) 152:48-55.
154. AMENTO EP, BECK LS: TGF-β and wound healing. CIBA Found. Symp. (1991) 157:115-123.
155. CROSS M, DEXTER TM: Growth factors in development, transformation, and tumorigenesis. Cell (1991) 64:271-280.
156. BARCELLOS-HOFF MH, DERYNCK R, TSANG ML-S, WEATHERBEE JA: Transforming growth factor-β activation in irradiated murine mammary gland. J. Clin. Invest. (1994) 93:892-899.
157. BARCELLOS-HOFF MH, EHRHART EJ, KALIA M et al.: Immunohistochemical detection of active TGF-β in situ using engineered tissue. Am. J. Pathol. (1995) 147:1228-1237.
158. EWAN KB, SHYAMALA G, RAVANI SA et al.: Latent TGF-β activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. Am. J. Path. (2002) 160:2081-2093.
159. BARCELLOS-HOFF MH: Latency and activation in the regulation of TGF-β. J. Mamm. Gland Biol. Neopl. (1996) 3:353-363.
160. DERYNCK R, ACKHURST RJ, BALMAIN A: TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. (2001) 29(2):117-129.
161. UEKI N, NAKAZATO M, OHKAWA T et al.: Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta. (1992) 1137-186-196.
162. IOZZO RV, COHEN I: Altered proteoglycan gene expression and the tumor stroma. EXS (1994) 70:199-214.
163. MAHARA K, KATO J, TERUI T et al.: Transforming growth factor β1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. Br. J. Cancer (1994) 69:777-783.
164. +T cell function. Jpn. J. Cancer Res. (1993) 84:315-325.
165. HOJO M, MORIMOTO T, MALUCCIO M et al.: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 397:530-534.
166. PORTELLA G, CUMMING SA, LIDDELL J et al.: Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ. (1998) 9:393-404.
167. BHOWMICK NA, GHIASSI M, BAKIN A et al.: Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a Rho-A-dependent mechanism. Mol. Biol. Cell (2001) 12:27-36.
168. GORSCH SM, MEMOLI VA, STUKEL TA, GOLD LI, ARRICK BA: Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res. (1992) 52:6949-6952.
169. MCCUNE BK, MULLIN BR, FLANDERS KC et al.: Localization of transforming growth factor-β isotypes in lesions of the human breast. Human Pathol. (1992) 23:13-20.
170. DALAL BI, KEOWN PA, GREENBERG AH: Immunocytochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am. J. Pathol. (1993) 143:381-389.
171. BARRETT-LEE P, TRAVERS M, LUQMANI Y, COOMBES RC: Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br. J. Cancer (1990) 61:612-617.
172. MURRAY PA, BARRETT-LEE P, TRAVERS M et al.: The prognostic significance of transforming growth factors in human breast cancer. Br. J. Cancer (1993) 67:1408-1412.
173. BUTTA A, MACLENNAN K, FLANDERS KC et al.: Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. (1992) 52:4261-4264.
174. DUBLIN EA, BARNES DM, WANG DY, KING RJ, LEVISON DA: TGF α and TGF β expression in mammary carcinoma. J. Pathol. (1993) 170:15-22.
175. GODDEN J, PORTEOUS C, GEORGE WD, KERR DJ: Bioassay of transforming growth factor-β activity in acidic protein extracts from primary breast cancer specimens. Anti-Cancer Res. (1993) 13:427-431.
176. DICKENS T, COLLETTA AA: The pharmacological manipulation of members of the transforming growth factor β family in the chemoprevention of breast cancer. BioEssays (1993) 15:71-74.
177. BARCELLOS-HOFF MH: Radiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res. (1993) 53:3880-3886.
178. JIRTLE RL, HAAG JD, ARIAZI EA, GOULD MN: Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor β1 levels during monoterpene-induced regression of mammary tumors. Cancer Res. (1993) 53:3849-3852.
179. MUIR GH, BUTTA A, SHEARER RJ et al.: Induction of transforming growth factor β in hormonally treated human prostate cancer. Br. J. Cancer (1994) 69:130-134.
180. REISS M, BARCELLOS-HOFF MH: Transforming growth factor-β in breast cancer: a working hypothesis. Br. Cancer Res. Treat. (1997) 45:81-95.
181. MURAOKA RS, DUMONT N, RITTER CA et al.: Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. (2002) 109:1551-1559.
182. YANG Y-A, DUKHANINA O, TANG B et al.: Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. (2002) 109:1607-1615.
183. AKHURST RJ: TGF-β antagonists: why suppress a tumor suppressor? J. Clin. Invest. (2002) 109:1533-1536.
184. PARVIN B, YANG Q, FONTENAY G, BARCELLOS-HOFF MH: BioSig: an imaging bioinformatics system for studying phenomics. IEEE Computer (2002) 35:65-71.